Skip to main content

Pharming Group N.V. announces today updated full year 2023 guidance, including RUCONEST® and Joenja® revenues, and a progress update on the U.S. launch of Joenja® (leniolisib) for APDS. For the full year 2023, total revenues are expected to increase by 19% to approximately US$245 million (preliminary and unaudited*).

"We are pleased to have concluded an excellent year in which we transformed Pharming into a multi-product, commercial rare disease biopharmaceutical company."

- Sijmen de Vries | Chief Executive Officer
Cookies: This website uses cookies Check the cookies page for more information Accept Decline